Table of Contents
Overview
New York, NY – July 16, 2025 : The Global Sustained Release Excipients Market is expected to grow from USD 1.4 billion in 2023 to USD 3.2 billion by 2033. This reflects a CAGR of 8.5% during the forecast period. North America led the market with over 42.4% share, reaching USD 0.6 billion in value. The market is growing due to the rising demand for controlled and targeted drug delivery. Sustained release excipients help maintain a consistent drug release, which improves treatment outcomes and enhances patient compliance in long-term therapies.
These excipients are vital in the development of oral tablets, capsules, and injectables. They enable the controlled release of active ingredients, which is crucial for maximizing efficacy and minimizing side effects. Their importance has grown with the shift toward more personalized medicine. Pharmaceutical companies are increasingly adopting sustained release excipients to create drugs with longer action and reduced dosing frequency. This approach boosts both treatment effectiveness and patient satisfaction, especially for chronic disease therapies that require precise dosage timing.
Personalized medicine is a major factor propelling the market forward. Sustained release excipients support tailored treatment by delivering drugs at specific rates and locations in the body. This targeted approach reduces the risk of side effects and enhances therapeutic response. These excipients are especially useful in complex formulations, where conventional drug delivery methods fall short. As healthcare moves toward individualized care, demand for high-performance excipients that ensure accurate drug delivery is rising across pharmaceutical and biotechnology sectors.
In February 2022, Oakrum Pharma LLC, in collaboration with ANI Pharmaceuticals, received FDA approval for a generic version of Cystadane. This product uses sustained release technology, highlighting its value in the generic drug space. The approval also granted 180-day market exclusivity under the Competitive Generic Therapy program. This example illustrates how sustained release excipients are becoming central to gaining regulatory advantages and commercial success. Companies that innovate in this area can secure both competitive positioning and improved patient outcomes.
Research and development in sustained release excipients is accelerating. Innovations focus on improving bioavailability and creating excipients tailored for biologics and complex drugs. Nanotechnology and site-specific delivery methods are emerging as key trends. These advances allow for more precise control of drug release, meeting modern therapeutic needs. As new drug formulations become more intricate, the need for advanced excipients will only grow. The market is poised for significant expansion, supported by continuous R&D, regulatory support, and the shift toward precision medicine.
Key Takeaways
- In 2023, the Sustained Release Excipients market earned around US$ 1.4 billion and is projected to hit US$ 3.2 billion by 2033.
- The market is expected to grow steadily at a CAGR of 8.5% over the forecast period from 2024 to 2033.
- Among product types, polymers dominated the market in 2023, accounting for the highest share at 39.2% due to their wide pharmaceutical application.
- Based on the route of administration, oral formulations led the market with a significant 48.9% share in 2023, driven by patient preference.
- In terms of technology, targeted delivery methods emerged as the leader, capturing a 37.4% share of the global market in 2023.
- North America held the largest regional share at 42.4%, reflecting strong demand, robust healthcare infrastructure, and advanced pharmaceutical research.
Regional Analysis
North America holds the largest share in the sustained release excipients market, accounting for 42.4% of the revenue. This growth is driven by advancements in drug formulations and a rising demand for controlled-release medications. The preference for once-daily doses has improved patient compliance and convenience. A key example is Athena Bioscience’s 2022 launch of Nexiclon XR, an extended-release clonidine tablet. The region also benefits from a high prevalence of chronic diseases like hypertension and diabetes, which increases the need for long-acting drug delivery systems.
The Asia Pacific region is expected to grow at the fastest CAGR in the forecast period. This is due to expanding healthcare access, rising chronic illness rates, and better pharmaceutical production. Countries like India and China are boosting demand for sustained release formulations. In 2022, Dr. Reddy’s launched generic Fesoterodine Fumarate ER tablets in the U.S., showing regional capability. Growth is further driven by higher disposable income, better awareness, and cost-effective generics. Investments in R&D will continue to support market expansion in Asia Pacific.
Segmentation Analysis
Product Type Analysis
In 2023, the polymers segment led the sustained release excipients market with a 39.2% share. This dominance is due to their wide use in drug formulations for controlled and sustained release. Polymers are popular for their ability to modify drug release rates and improve stability. Their role in enhancing patient compliance makes them a preferred choice in the industry. With advancements in biodegradable and biocompatible polymers, the segment is expected to grow steadily, especially in targeted therapies for chronic health conditions.
Route of Administration Analysis
The oral segment captured a 48.9% market share in 2023, driven by convenience and strong patient compliance. Oral formulations are cost-effective and easy to administer, making them a popular route. The shift toward once-daily medications boosts demand for sustained release excipients. Chronic diseases like diabetes and heart conditions further drive the need for long-term, effective oral therapies. Pharmaceutical companies are also focusing on improving drug bioavailability and performance, supporting the steady growth of oral sustained release products in the coming years.
Technology Analysis
Targeted delivery technology accounted for a 37.4% revenue share in 2023, thanks to rising demand for precision medicine. These systems improve treatment by delivering drugs directly to the affected area. This approach minimizes side effects and improves drug absorption. Techniques like microencapsulation and the Wurster method enhance release control. The growth of diseases such as cancer and autoimmune disorders is also fueling demand for advanced delivery methods. As personalized medicine expands, targeted delivery is expected to see continued and significant growth in the market.
Key Players Analysis
The major players in the Sustained Release Excipients market are actively introducing innovative products and implementing strategic growth initiatives. These companies focus on expanding their product portfolios, leveraging technology, and forming strategic partnerships. Research and development is a key area of investment, aiming to improve excipient performance and drug release control. Partnerships with pharmaceutical firms and contract research organizations help boost market adoption. Players are also targeting emerging regions due to rising demand for controlled-release formulations, positioning themselves for long-term market presence.
One leading company, Ashland Global Holdings, plays a vital role in this market. Known for its pharmaceutical excipients, Ashland supports sustained release drug applications. Its strategy includes product innovation, global expansion, and strategic acquisitions. The company also invests in developing eco-friendly excipients to meet growing sustainability standards. Ashland focuses on offering customized excipient solutions to pharmaceutical companies. This helps improve drug delivery systems and patient outcomes. Its strong emphasis on R&D keeps it competitive in the evolving pharmaceutical landscape.
Emerging Trends
Shift Toward Patient-Centric Drug Formulations
Pharmaceutical companies are focusing more on making drugs easier for patients to take. One key way to do this is by using sustained release excipients. These excipients help drugs work over a longer time, so patients don’t need to take them as often. This is especially helpful for people with chronic illnesses who require daily treatment. Reducing the number of doses improves convenience and helps patients stick to their treatment. As a result, many companies are now investing in long-acting drug formulations. This trend supports better patient outcomes and is expected to grow as healthcare becomes more patient-focused.
Increased Use of Natural and Biodegradable Polymers
There is a clear shift toward using natural and eco-friendly materials in drug development. In the sustained release excipients market, plant-based and biodegradable polymers are gaining attention. Examples include cellulose derivatives and other naturally sourced materials. These ingredients are safer for long-term use and pose less risk of side effects. They are also better for the environment. Patients and regulators alike prefer these sustainable options. As a result, pharmaceutical companies are testing and adopting natural polymers more than ever. This trend is expected to shape future drug delivery systems in both oral and injectable forms.
Advancements in Drug Delivery Technologies
Modern drug delivery systems are getting more complex. Technologies like microspheres, matrix tablets, and multi-layer pills need advanced excipients. These excipients must control when and how drugs are released in the body. Sustained release excipients play a key role in this process. They help ensure that drugs work over time without needing frequent doses. With more drugs now requiring timed release, the demand for innovative excipients is rising. Pharmaceutical companies are investing in research to develop excipients that match these needs. This trend is expected to drive the next wave of drug delivery advancements.
Growing Role in Personalized Medicine
Personalized medicine is changing how treatments are made and given to patients. Instead of one-size-fits-all drugs, companies now design medicines for specific people or conditions. Sustained release excipients support this approach. They allow drugs to release at a controlled rate, which helps doctors fine-tune treatment plans. This control makes it easier to meet a patient’s unique needs. It also improves how effective and safe the drug is. As personalized medicine becomes more popular, the demand for reliable sustained release excipients will increase. This trend is helping push innovation in drug design and formulation.
Expansion of Oral and Injectable SR Formulations
Sustained release excipients are mostly used in oral tablets, but their use is expanding. New research shows they are also useful in long-acting injectables. These include treatments for conditions like diabetes, hormone imbalance, or mental health issues. In these cases, patients benefit from fewer injections over time. Advances in excipient technology now make it easier to control how injectable drugs work. As a result, more companies are exploring these options. This trend is broadening the scope of sustained release excipients and increasing their importance across different types of drug delivery systems.
Regulatory Push for Consistency and Safety
Health authorities around the world are pushing for safer and more reliable drug ingredients. This includes excipients used in sustained release medications. Regulators want drugs to release their active ingredients in a consistent and controlled way. They also want excipients that have a proven safety record. Because of this, pharmaceutical companies are choosing excipients that meet strict quality standards. This trend is driving demand for excipients that are well-tested and regulatory-approved. It also ensures better patient safety and more predictable treatment outcomes. Regulatory focus is expected to play a key role in shaping future excipient use.
Use Cases
1. Chronic Disease Treatment
Patients with long-term conditions like diabetes, arthritis, or high blood pressure often need regular medication. Sustained release excipients help by releasing the drug slowly over time. This keeps the medication levels stable in the body. As a result, patients don’t have to take their medicine multiple times a day. This is especially useful for people who may forget doses or find frequent dosing hard to manage. With fewer doses and better control, treatment becomes easier and more effective. For chronic illness management, this approach supports better patient compliance and overall health outcomes.
2. Pain Management Medications
People dealing with long-lasting pain, such as post-surgery recovery or chronic pain conditions, need steady relief. Pain relievers that use sustained release excipients work slowly and steadily. This means the drug stays active in the body longer. Patients don’t have to take medicine several times a day. This improves comfort and allows for uninterrupted sleep or daily activities. Sustained release pain meds also lower the chances of sudden spikes or drops in pain control. For both doctors and patients, this offers a more convenient and consistent pain management solution.
3. Mental Health and Neurological Disorders
Mental health conditions like depression, schizophrenia, and epilepsy require consistent medication. Any sudden change in drug levels can cause side effects or reduce the treatment’s impact. Sustained release excipients help keep drug levels steady throughout the day. This avoids the highs and lows that come with traditional pills. It also means fewer doses are needed. This helps patients stick to their treatment plan better. In mental health care, reliable drug delivery is key. Sustained release medications improve therapy results and reduce the risk of relapse or complications.
4. Pediatric and Geriatric Medications
Children and older adults often struggle with multiple daily doses. They may forget or find it hard to swallow pills. Sustained release excipients make this easier. By releasing the drug slowly, one pill can work for hours. This means fewer doses in a day. It also makes treatment less stressful for caregivers and family members. Kids and seniors benefit from simpler medication routines. It improves safety, comfort, and treatment success. For these age groups, sustained release forms offer a user-friendly and effective solution for many types of medications.
5. Veterinary Medicine
Animals, like humans, need consistent medication—especially for long-term or chronic issues. But giving pets or livestock several doses a day is tough. Sustained release excipients help by allowing the drug to release slowly. This means fewer doses and less stress for the animal. It also saves time for pet owners, vets, and farmers. With longer-acting medicines, animals stay healthier and are easier to manage. From household pets to large farm animals, sustained release drugs improve treatment results and simplify care routines in veterinary medicine.
6. Oncology Therapies
Cancer treatment is often intense and demanding. Some therapies use sustained release excipients to make it more manageable. These excipients allow chemotherapy drugs to release slowly into the body. This can reduce harsh side effects and make patients feel more comfortable between treatments. It also helps maintain steady drug levels, which is important for stopping cancer cells from growing. For patients, this means fewer clinic visits and a better quality of life. In oncology, sustained release methods are improving how cancer care is delivered and experienced.
Conclusion
In conclusion, the sustained release excipients market is growing steadily due to rising demand for long-acting and patient-friendly drug formulations. These excipients help improve treatment outcomes by ensuring controlled and consistent drug release. They are widely used in therapies for chronic conditions, mental health, and pain management, making daily medication easier for patients. With advancements in personalized medicine and drug delivery technology, their importance is set to increase. Companies are focusing on innovation, eco-friendly materials, and strategic partnerships to stay competitive. As healthcare becomes more targeted and patient-centric, the role of sustained release excipients will continue to expand across global pharmaceutical and biotech industries.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
